New pill targets Hard-to-Treat lymphoma in early human test
NCT ID NCT05824585
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This early-stage trial tests an experimental oral drug called DZD8586 in adults with B-cell Non-Hodgkin lymphoma that has returned or stopped responding to standard treatments. The study aims to find a safe dose and check whether the drug can shrink tumors. Participants take the pill once daily, and researchers monitor side effects, drug levels in the body, and anti-cancer activity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DZD8586
What this could lead to
If successful, this could lead to a new oral treatment option for people with B-cell Non-Hodgkin lymphoma who have not responded to other therapies.
What could go wrong
This is an early Phase 1 trial with only 17 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, NON-HODGKIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Toxin Exposure & NHL in Military: NCT07652580
- Stem Cell Transplant Study for Blood Cancers NCT05800210
- Fecal Transplant to Prevent GvHD After Stem Cell NCT04935684
- CAR T-Cell Therapy for Lymphoma Relapse Preventi NCT02663297
- ONO-7018 for NHL or CLL: Phase 1 Trial (NCT05515406)
- Pneumococcal Vaccine Study in Lymphoma Patients NCT04460235
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research site
New York, New York, 10065, United States
-
Research site
Albury, New South Wales, Australia
-
Research site
Ballarat, Victoria, Australia
-
Research site
Melbourne, Victoria, Australia
-
Research site
Perth, Western Australia, Australia